NCT02578940View on ClinicalTrials.gov

Fluciclovine (18F) PET/CT in biochemicAL reCurrence Of Prostate caNcer

PHASE3CompletedINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

May 17, 2017

Study Completion Date

June 22, 2018

Conditions
Cancer of the Prostate
Interventions
DRUG

18F-Fluciclovine PET CT

Radioligand for PET CT scanning

Trial Locations (7)

HA6 2RN

Mount Vernon Cancer Centre, Mount Vernon Hospital, Northwood

OX3 7LE

Churchill Hospital, Oxford

SM2 5PT

Royal Marsden Hospital, Sutton

LS9 7TF

St James Institute of Oncology, Leeds

Unknown

Greater Glasgow & Clyde NHS Trust, Glasgow

NW1 2BU

University College London Hospital, London

SE1 7EH

St Thomas' Hospital, London

Sponsors

Collaborators (1)

Innovate UK
All Listed Sponsors
collaborator

Innovate UK

OTHER_GOV

collaborator

Syne Qua Non Limited

INDUSTRY

collaborator

IND 2 Results LLC

INDUSTRY

lead

Blue Earth Diagnostics

INDUSTRY

NCT02578940 - Fluciclovine (18F) PET/CT in biochemicAL reCurrence Of Prostate caNcer | Biotech Hunter | Biotech Hunter